A Phase III Observer-Blind, Randomized, Controlled, Single-Coordinating Center Pediatric Study in China Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Using a Local Dosing Regimen in Infants.

Trial Profile

A Phase III Observer-Blind, Randomized, Controlled, Single-Coordinating Center Pediatric Study in China Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Using a Local Dosing Regimen in Infants.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2013

At a glance

  • Drugs TAK 816 (Primary) ; Hib vaccine conjugate
  • Indications Haemophilus infections
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 22 Aug 2013 Results published in the International Journal of Clinical Practice.
    • 24 Oct 2011 Actual end date Dec 2010 added as reported by ClinicalTrials.gov.
    • 24 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top